Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
Date:1/26/2012

MALVERN, Pa., Jan. 26, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the first cohort of patients has been dosed in its phase Ib trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite.  Cellulite has been reported to occur in 85-98% of post-pubertal females and rarely in men.  The condition is prevalent in women of all races. (1,3)

(Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

Cellulite is described as a localized metabolic disorder of tissue under the skin, which can involve the loss of elasticity or shrinking of collagen cords, called septae, that attach the skin to lower layers of muscle. When fat in cellulite prone areas swells and expands, the septae tether the skin, which causes surface dimpling characteristic of cellulite.  XIAFLEX treatment is intended to target and lyse, or break, those collagen tethers with the goal of releasing the skin dimpling and potentially resulting in smoothing of the skin.  

"For many women, cellulite can be a source of considerable embarrassment or self-consciousness," said Dr. James Tursi, Chief Medical Officer at Auxilium. "Current treatments of cellulite with creams, light-based procedures or liposuction provide limited or no effectiveness. The clinical development of XIAFLEX, if successful, could lead to the first FDA-approved, office-based medical treatment option that is supported by scientific results."

The phase Ib study is a single site, open-label dose-escalation study that is targeted to enroll 63 women between 21 and 60 years of age. The objectives of the study are to assess the safety, effectivene
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... has completed enrollment of the additional subjects, as ... this year, into the company,s Phase 2 study ... regulator (IDR) and is being evaluated as a ...
(Date:8/31/2015)... August 31, 2015 Premune ... into an exclusive licensing agreement for Redonyl ® ... $300 million USD veterinary dermatology market, is a nutritional ... support healthy skin in dogs and cats. Redonyl ® ... , and has been received positively in the ...
(Date:8/31/2015)... Aug. 31, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY), ... of innovative therapeutics for the treatment of diseases of ... that its BNC101 IND submission has passed review by ... to initiate a Phase 1 clinical trial in patients ... pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... ATS Medical, Inc. (Nasdaq: ATSI ), manufacturer and ... it will participate in the 2009 Canaccord Adams Cardiovascular ... Dale, President and CEO of ATS Medical, will present ... 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , Attendance at ...
... 3 Robert Mazzacavallo has joined Veridiam as the ... contract manufacturer of high-precision, fabricated assemblies and metal components, ... power generation, aerospace and general industrial markets. , Before ... Industries in Camas, WA. At C-Tech, Bob worked ...
Cached Medicine Technology:ATS Medical to Participate in the 2009 Canaccord Adams Cardiovascular Conference 2Veridiam Names Robert Mazzacavallo New CFO 2
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... Patients ... from and those who are interested in learning more about the procedure beyond the ... Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be on hand ...
(Date:8/31/2015)... ... 31, 2015 , ... The Sundance Film Festival award winning documentary “Alive Inside” ... Inside” shadows a social worker who advocates for the use of music therapy for ... music to residents in health care centers who may have lost a spark in ...
(Date:8/31/2015)... ... August 31, 2015 , ... Garden ... in 2008, the result of a merger of five of the busiest urology ... they could provide more cost-effective and higher quality care than they did individually. ...
(Date:8/31/2015)... ... 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed ... Dr. Michael Betsy graduated from Don Bosco Prep in 1990 and was Class Salutatorian. ... both sports in his senior year. He was inducted into the National Honor Society ...
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... how it may be prevented during Amblyopia Awareness Month. Only a comprehensive eye examination ... the most common cause of visual impairment among children, affecting approximately 2 to 3 ...
Breaking Medicine News(10 mins):Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3
... Serena Gordon HealthDay Reporter , THURSDAY, Jan. 13 ... SAT that,s got your teen,s stomach tied up in knots, ... scores. New research, published in the Jan. 14 issue ... minutes writing about their test anxiety and fears just before ...
... Drugs that pharmaceutical companies market most aggressively to physicians and ... most patients a phenomenon described as the "inverse benefit ... Branch at Galveston. Published online Thursday, Jan. 13 ... article explores recent withdrawals of blockbuster drugs due to safety ...
... (MGH) Cancer Center researchers have discovered a previously unknown feature ... sequences that do not code for proteins. These DNA ... their role in chromosomal structure but previously were not suspected ... appear in the journal Science and is receiving ...
... , THURSDAY, Jan. 13 (HealthDay News) -- In an unscripted ... Tucson and America" memorial, President Barack Obama said Rep. Gabrielle ... and her husband Mark Kelly at University Medical Center in ... to House Minority Leader Nancy Pelosi (D-Calif.) confirmed that Pelosi, ...
... and reconstructed the genomes of most of the ... and documented how the microbe populations changed over ... eventually help researchers understand the causes of various ... sometimes fatal necrotizing enterocolitis, according to researchers at ...
... programs that put them behind the wheelin a driving simulator, ... the conclusion of a new article published in Current ... for Psychological Science. Older people are at much ... and provinces test older drivers, hoping to get the riskiest ...
Cached Medicine News:Health News:Write Your Test Stress Away 2Health News:Write Your Test Stress Away 3Health News:Inverse benefits due to drug marketing undermine patient safety and public health 2Health News:Inverse benefits due to drug marketing undermine patient safety and public health 3Health News:Overexpression of repetitive DNA sequences discovered in common tumor cells 2Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 2Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 3Health News:Scientists sequence gut microbes of premature infant 2Health News:Scientists sequence gut microbes of premature infant 3Health News:Scientists sequence gut microbes of premature infant 4Health News:Scientists sequence gut microbes of premature infant 5Health News:Driving simulators help older adults improve their road skills 2
... Artemis is the world's first very high ... 3D Arc-scanning technology, Artemis provides microscopic resolution ... cornea and anterior segments of the human ... (VHF) ultrasound eye scanner. In use, the ...
The UD-6000 combines all the functions of modern ultrasound diagnostics used in ophthalmology: The latest generation high resolution A/B-sector scanner, a diagnostic A-mode scanner with an optional p...
... is a sensitive B-scan system which quickly identifies ... of both eyes differ by more than 0.3 ... be suspected. The B5500 enables quick and easy ... water bath or inserting shells under the lids. ...
... CineScan A/B represent a true breakthrough in ... with technology and diagnostic capability previously unavailable. ... vitreous. Adjust the gain up to 105db ... invisible at a standard 90db setting - ...
Medicine Products: